Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Schmitz-Peiffer

 

Skeletal muscle is one of the major insulin-responsive tissues involved in the regulation of blood glucose levels. Muscle becomes insulin resistant with increased fat availability and obesity, and this resistance is strongly linked to cardiovascular disease, hypertension and type 2 diabetes (the "Metabolic Syndrome"). The molecular mechanisms linking lipid oversupply to the inhibition of insulin action in muscle are, however, poorly understood. Our group uses animal and cell models of lipid-induced insulin resistance to investigate the role of lipid species and signalling pathways in the inhibition of insulin signal transduction, with particular emphasis on isoforms of the lipid-activated protein kinase C (PKC) family.

Lipid-Induced Insulin Resistance in Skeletal Muscle
Using cultured skeletal muscle cells treated with fatty acids as a model of obesity and insulin resistance, we have identified lipid intermediates which inhibit insulin signal transduction. Further work will investigate the activation of inhibitory pathways and gene expression, which in turn act to block insulin signalling and normal glucose metabolism.

The Role of PKC in Glucose Homeostasis
Our current studies using PKC knockout mice indicate that these kinases contribute to glucose intolerance caused by lipid oversupply by distinct actions in pancreatic islets and insulin target tissues. We are now investigating these at both whole-body and mechanistic levels, using tissue-specific knockout mice and cell models. A novel direction is the investigation of the role of PKC in insulin receptor internalization whihc regulates insulin clearance from the circulation by the liver and thus determines the availability of the hormone to its target tissues.

PKC Substrates and Regulatory Proteins
We are identifying proteins both up- and downstream of PKC isoforms which play a role in the inhibitory signalling affecting both insluin secretion and insulin action, employing molecular, biochemical and proteomic techniques.

 

Staff

 

David PedersenPhD Student
David Pedersen
katy_raddatzResearch Officer
Dr Katy Raddatz
georgia_frangioudakis90.jpgResearch Officer
Dr Georgia Frangioudakis
Mana LiaoResearch Assistant
Mana Liao

 

 

See also:

Biden Research Group

Laybutt Research Group

 

News

 

Solving a critical part of the insulin puzzle

MEDIA RELEASE: 04 Oct 2007
We are now one step closer to improved treatment of Type 2 diabetes following significant findings made by scientists at the Garvan Institute of Medical Research. The team from Garvan's Diabetes Signalling Unit, led by Associate Professor Trevor Biden and Dr Carsten Schmitz-Peiffer, has identified a very important biological target that will enable them to address one of the major underlying causes of diabetes.
 
 

Personal tools